News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Sees Side Effects With ThromboGenics NV (TBGNF)'s Eye Drug



7/25/2012 7:13:37 AM

ThromboGenics NV (THR) fell as much as 19 percent after the U.S. Food and Drug Administration said it had concerns about the safety of the company’s eye drug. The shares traded 8.8 percent lower at 22.83 euros as of 2:52 p.m in Brussels. The intraday decline is the steepest since June 5. Side effects including eye pain, perceived flashes of light, blurred vision and impaired vision happened two to four times more often in patients receiving ocriplasmin than those getting a placebo in a trial, the FDA said in a staff report today.

Read at BusinessWeek
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES